Bausch + Lomb Corporation logo BLCO - Bausch + Lomb Corporation

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 8
HOLD 8
SELL 1
STRONG
SELL 0
| PRICE TARGET: $20.83 DETAILS
HIGH: $24.00
LOW: $16.00
MEDIAN: $22.00
CONSENSUS: $20.83
UPSIDE: 21.46%

Stock News

Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting

Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced progress in the development of BL1243 (tonabersat), an investigational oral treatment for dry age-related macular degeneration (AMD), following a constructive meeting with the U.S. Food and Drug Administration (FDA). The discussion provided greater clarity on the clinical development path for BL1243. If successf.

Oct 06, 2026 12:30 PM • businesswire.com
Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28

Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter financial results on Wednesday, Oct. 28, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the c.

Oct 05, 2026 03:30 AM • businesswire.com
Financial Survey: Merit Medical Systems (NASDAQ:MMSI) vs. Bausch + Lomb (NYSE:BLCO)

Financial Survey: Merit Medical Systems (NASDAQ:MMSI) vs. Bausch + Lomb (NYSE:BLCO)

Merit Medical Systems (NASDAQ: MMSI - Get Free Report) and Bausch + Lomb (NYSE: BLCO - Get Free Report) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk. Institutional and Insider Ownership 99.7%

Sep 23, 2026 10:29 PM • defenseworld.net
Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser

Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced European CE Mark approval of SeeLyra, the company's next generation femtosecond laser. One of the most compact femtosecond platforms available, SeeLyra provides surgeons precision and control when performing laser preparation for premium cataract, LASIK flap and corneal therapeutic surgeries while simultaneously.

Sep 11, 2026 02:11 AM • businesswire.com
Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience

Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the publication of new research on real world experience with enVista Aspire and enVista Aspire toric intraocular lenses (IOLs). The study, published in the journal Ophthalmology and Therapy, found that these enhanced monofocal lenses delivered both good distance and functional intermediate vision, thus meeting.

Sep 02, 2026 03:00 AM • businesswire.com
Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds

Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced findings from a new survey highlighting a significant awareness gap around dry eye and its association with perimenopause and menopause. The survey found that dry eye remains one of the least recognized symptoms experienced during these stages of life. According to the survey, only 14% of peri-, menopausal and p.

Sep 01, 2026 02:58 AM • businesswire.com
Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance

Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced changes to its Board of Directors. At the request of Bausch Health Companies Inc. (“Bausch Health”), which has held a majority ownership position in Bausch + Lomb since its initial public offering in 2022 and currently owns, directly or indirectly through its wholly owned subsidiaries, approximately 87% of the c.

Aug 06, 2026 03:00 AM • businesswire.com
Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance

Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its second-quarter 2026 financial results. “Broad-based revenue growth, leverage in the P&L, margin expansion and conversion to cash flow. These have been themes since we unveiled our three-year plan for growth at Investor Day last November, and in the second quarter progress continued at an accelerated pace.

Jul 29, 2026 02:58 AM • businesswire.com
Bausch + Lomb Launches EyeGility™ Inserter Preloaded IOL Delivery System in the United States

Bausch + Lomb Launches EyeGility™ Inserter Preloaded IOL Delivery System in the United States

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of the EyeGility™ Inserter preloaded IOL delivery system. “The enVista IOL platform has long been appreciated by surgeons for its glistening-free optic and differentiated optic portfolio to suit a wide range of patients,” said Wayne Caulder, vice president and general manager, North America Surgi.

Jul 16, 2026 03:00 AM • businesswire.com

Price Targets